• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 520634 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414772009 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414772009 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Biogen Idec (BIIB) Approaches New Downside Target of $198.55

Published on Thu, 06/20/2013 - 13:04
By Adrienne Chilton

Shares of Biogen Idec (NASDAQ:BIIB) opened today below their pivot of $206.22 and have already reached the first level of support at $201.17. Should the shares continue to fall, the support pivots of $198.55 and $190.88 will be of interest.

Biogen Idec share prices have moved between a 52-week high of $242.64 and a 52-week low of $134.00 and are now trading 50% above that low price at $200.55 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.5% while the 50-day MA has advanced 0.4%.

Potential upside of 11.1% exists for Biogen Idec, based on a current level of $200.55 and analysts' average consensus price target of $222.86. The stock should find resistance at its 50-day moving average (MA) of $217.64, as well as support at its 200-day MA of $171.25.

Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Dr Reddys Laboratories Makes a Move: Up ...

Dr Reddys Laboratories (NYSE:RDY) is a company whose shares are active, trading 2.4% hi ...

Hill International is Among the Companie...

Below are the three companies in the Research and Consulting Services industry with the ...

NPS Pharmaceuticals Bearish Moving Avera...

Today, shares of NPS Pharmaceuticals (NASDAQ:NPSP) have fallen below their 10-day MA of ...

Buyers Accumulate Shares of Herbalife, U...

One of today's stocks on the move is Herbalife (NYSE:HLF), up 2.5% to $51.80. The S&P ...

Highest Projected Earnings Growth in the...

Below are the three companies in the Managed Health Care industry with the highest proj ...

Post Properties Bullish Moving Average C...

Post Properties (NYSE:PPS) shares have crossed bullishly above their 10-day moving aver ...

Shares of Western Union Receive a Boost,...

Western Union (NYSE:WU) is one of today's biggest movers, up 2.5% to $17.11. The Dow J ...

Westlake Chemical Ranks the Highest in T...

Below are the three companies in the Commodity Chemicals industry with the highest proj ...